Sign In
Buy VERA
$41.50
-0.500 (-1.19%)
At Close: Jul 13, 2026
Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch
02:02pm, Saturday, 11'th Jul 2026
Vera Therapeutics NASDAQ: VERA said the U.S. Food and Drug Administration granted accelerated approval to TRUTAKNA, or atacicept-vymj, for adults with primary IgA nephropathy at risk for disease progr
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 10'th Jul 2026
BRISBANE, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on July 6, 2026, the Compensation Committee of the Board of Directors (Compensation Com
Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner
08:00am, Thursday, 09'th Jul 2026
BRISBANE, Calif., July 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced a planned transition of the Chief Regulatory Offic
Vera Therapeutics, Inc. (VERA) Discusses Accelerated FDA Approval of TRUTAKNA for IgA Nephropathy Transcript
07:12pm, Tuesday, 07'th Jul 2026
Vera Therapeutics, Inc. (VERA) Discusses Accelerated FDA Approval of TRUTAKNA for IgA Nephropathy Transcript
US FDA approves Vera's kidney disease drug
12:42pm, Tuesday, 07'th Jul 2026
The U.S. Food and Drug Administration has approved Vera Therapeutics' drug to treat patients with a potentially life-threatening kidney disease, the regulator said on Tuesday, sending i
Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy
12:37pm, Tuesday, 07'th Jul 2026
TRUTAKNA is the first and only available therapy that binds both B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), addressing the immunological drivers at the source of IgA
What's Going on with Vera Therapeutics Stock on Monday?
11:39am, Monday, 06'th Jul 2026
Investors are closely watching Vera Therapeutics Inc. (NASDAQ:VERA) as the company awaits the U.S. Food and Drug Administration (FDA) decision for its rare kidney disease drug.
3 Biotech Firms With Major Potential Catalysts in the Coming Months
05:35pm, Tuesday, 23'rd Jun 2026
As Big Pharma braces for a looming patent cliff that threatens billions in revenue, a different group of companies is chasing the opposite story: a single breakthrough that could define their future.
3 Biotech Firms With Major Potential Catalysts in the Coming Months
10:31am, Sunday, 21'st Jun 2026
As Big Pharma braces for a looming patent cliff that threatens billions in revenue, a different group of companies is chasing the opposite story: a single breakthrough that could define their future.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 05'th Jun 2026
BRISBANE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on June 2, 2026, the Compensation Committee of the Board of Directors (Compensation Com
$20 Billion: Inside Nvidia's VERA CPU Bet to Break the Intel-AMD Duopoly
09:29am, Thursday, 04'th Jun 2026
You can argue about almost every line in a NVIDIA (NASDAQ:NVDA | NVDA Price Prediction) earnings release.
Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgAN
Investment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC Filing
02:29pm, Tuesday, 26'th May 2026
This biotech focuses on biologic therapies for immunological diseases, with lead candidates in nephrology and infectious disease.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 08'th May 2026
BRISBANE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on May 4, 2026, the Compensation Committee of the Board of Directors (Compensation Commi
Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
07:30am, Thursday, 07'th May 2026
U.S. Food and Drug Administration (FDA) granted priority review to Biologics License Application (BLA) for the accelerated approval of atacicept in adult patients with IgA Nephropathy (IgAN) with a Pr
